Clinical Trial Update: Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity study of a meningococcal serogroup C vaccine produced by Bio-Manguinhos in young adults has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis Serogroup

Drugs mentioned

• Meningococcal serogroup C vaccine (Bio-Manguinhos) (Meningococcal serogroup C vaccine)

Snippet

Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Conditions: Meningitis, Meningococcal, Serogroup C | Phase 1 | Status: COMPLETED